Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$1.02 -2.9%	$0.98	$0.66 ▼ $17.75	$5.89M	0.15	795,268 shs	7,400 shs
CALC CalciMedica	$1.72 -2.0%	$1.77	$1.43 ▼ $6.02	$24.03M	1.24	45,641 shs	12,519 shs
CYCC Cyclacel Pharmaceuticals	$1.68 -4.0%	$3.55	$1.36 ▼ $49.34	$25.87M	0.52	109,821 shs	54,633 shs
DARE Daré Bioscience	$2.89 +0.5%	$2.91	$2.67 ▼ $6.24	$25.52M	1.2	36,482 shs	5,105 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-3.89%	-0.23%	+18.37%	-10.46%	-34.11%
CALC CalciMedica	-0.91%	-0.34%	+15.50%	-23.51%	-68.29%
CYCC Cyclacel Pharmaceuticals	+8.02%	+11.46%	-61.66%	-70.35%	-94.56%
DARE Daré Bioscience	+2.50%	-0.69%	-0.69%	-7.42%	-41.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	2.0331 of 5 stars	3.5	3.0	0.0	0.0	1.9	1.7	0.0
CYCC Cyclacel Pharmaceuticals	1.6041 of 5 stars	0.0	5.0	0.0	0.0	4.1	1.7	0.0
DARE Daré Bioscience	1.7391 of 5 stars	3.3	3.0	0.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
CALC CalciMedica	3.00	Buy	$18.00	946.51% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
DARE Daré Bioscience	2.50	Moderate Buy	$12.00	315.94% Upside

Current Analyst Ratings Breakdown

Latest ATNF, CALC, CYCC, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/10/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/1/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/22/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
3/7/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
3/4/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	($0.24) per share	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CYCC Cyclacel Pharmaceuticals	$14K	1,847.64	N/A	N/A	$0.57 per share	2.95
DARE Daré Bioscience	$25.91K	985.46	N/A	N/A	($0.61) per share	-4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$19.93M	N/A	0.00	∞	N/A	N/A	-558.93%	-54.10%	8/11/2025 (Estimated)
CALC CalciMedica	-$34.36M	-$1.56	N/A	N/A	N/A	N/A	-164.24%	-103.53%	8/11/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$56.00	N/A	∞	N/A	-18,150.00%	-1,901.11%	-188.23%	6/3/2025 (Estimated)
DARE Daré Bioscience	-$30.16M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-18.98%	8/11/2025 (Estimated)

Latest ATNF, CALC, CYCC, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q1 2025	CYCC Cyclacel Pharmaceuticals	-$0.29	-$0.33	-$0.04	N/A	$0.03 million	N/A
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/14/2025	Q1 2025	CALC CalciMedica	-$0.43	-$0.36	+$0.07	-$0.36	N/A	N/A
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
4/2/2025	Q4 2024	CYCC Cyclacel Pharmaceuticals	-$4.64	-$5.28	-$0.64	-$0.33	$0.01 million	$0.01 million
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/27/2025	Q4 2024	CALC CalciMedica	-$0.48	-$0.34	+$0.14	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	$0.15	8.93%	N/A	N/A	N/A
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A

Latest ATNF, CALC, CYCC, and DARE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/28/2025	CYCC Cyclacel Pharmaceuticals		$2.40		4/29/2025	4/29/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	0.19	0.19
CALC CalciMedica	N/A	4.15	4.15
CYCC Cyclacel Pharmaceuticals	N/A	0.77	0.77
DARE Daré Bioscience	N/A	1.14	1.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
CALC CalciMedica	N/A
CYCC Cyclacel Pharmaceuticals	23.58%
DARE Daré Bioscience	6.70%

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	0.17%
CALC CalciMedica	41.55%
CYCC Cyclacel Pharmaceuticals	68.00%
DARE Daré Bioscience	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	7	5.70 million	3.17 million	No Data
CALC CalciMedica	30	13.97 million	7.88 million	No Data
CYCC Cyclacel Pharmaceuticals	14	15.40 million	4.78 million	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable

ATNF, CALC, CYCC, and DARE Headlines

Recent News About These Companies

Daré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 17, 2025 | finanznachrichten.de

Q1 2025 Dare Bioscience Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Daré Bioscience outlines $4.5B hormone therapy market entry and expects Q4 2025 revenue as dual path strategy expands

May 14, 2025 | seekingalpha.com

DarÃ© Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2025 | zacks.com

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025 | globenewswire.com

Dare Bioscience's Earnings Outlook

May 12, 2025 | benzinga.com

'An unwinnable situation': FDA delays force one biopharma to shelve phase 3 plans, WSJ reports

April 18, 2025 | fiercebiotech.com

Drug Development Is Slowing Down After Cuts at the FDA

April 17, 2025 | msn.com

Dare Bioscience to present on expanded business strategy at Jones Conference

April 8, 2025 | markets.businessinsider.com

Maxim Group Keeps Their Hold Rating on Daré Bioscience (DARE)

April 5, 2025 | markets.businessinsider.com

Q4 2024 Dare Bioscience Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Dare Bioscience expects to start recording revenue, cash flow in Q425

April 1, 2025 | markets.businessinsider.com

Daré Bioscience targets Q4 2025 for Sildenafil Cream launch via 503B compounding

March 31, 2025 | msn.com

DarÃ© Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

March 31, 2025 | zacks.com

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

March 31, 2025 | globenewswire.com

Dare Bioscience Q4 2024 Earnings Preview

March 30, 2025 | msn.com

A Look Ahead: Dare Bioscience's Earnings Forecast

March 28, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?
By Jeffrey Neal Johnson | May 22, 2025
View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?

ATNF, CALC, CYCC, and DARE Company Descriptions

180 Life Sciences NASDAQ:ATNF

$1.02 -0.03 (-2.92%)

As of 11:44 AM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

CalciMedica NASDAQ:CALC

$1.72 -0.03 (-1.96%)

As of 11:29 AM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$1.68 -0.07 (-4.00%)

As of 11:46 AM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Daré Bioscience NASDAQ:DARE

$2.88 +0.02 (+0.52%)

As of 11:47 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time